Humacyte announces preclinical data on CTEV use

Humacyte (HUMA) announced the publication of new preclinical data as part of a study evaluating the coronary tissue engineered vessel, CTEV, as a coronary artery bypass graft conduit in a non-human primate model. In the study, published in JACC: Basic to Translational Science, a specialist journal launched by the Journal of the American College of Cardiology, JACC, the CTEV was observed to sustain blood flow, recellularize with the animals’ host cells, and remodel to reduce the initial size mismatch between the CTEV and the animals’ native artery. The recent JACC study, titled “Acellular Tissue Engineered Vessels as Coronary Artery Bypass Grafts”, follows five adult baboons undergoing CABG to the right coronary artery with the CTEV. At the end of follow-up, the CTEV was observed to have recellularized with host cells to form a multi-layered tissue, including transanastomotic neomedial tissue that effectively reduced the initial size mismatch with the right coronary artery. The results suggest that the CTEV may be a durable alternative CABG conduit.